Blog

Aggregation is considered the least wanted way of anonymization for several reasons, primarily due to its limitations in providing detailed and granular insights from the data. While aggregation offers privacy benefits by grouping data into broader categories, it can significantly reduce data utility and hinder the potential for meaningful analysis. Here are some reasons why […]

In today’s data-driven world, the use of health data has become a cornerstone of scientific research and healthcare decision-making. Administrative claim data, which contains a wealth of information about patients’ medical treatments and expenditures, is a valuable resource for understanding healthcare trends and improving patient outcomes. However, releasing such data without proper safeguards can jeopardize […]

The oncology patient pathway includes a series of steps that a cancer patient goes through: from diagnosis to treatment and beyond. It considers all aspects of care including diagnoses, treatment planning, care delivery, follow-up care, and end-of-life care. The cancer patient journey is ideally designed to provide comprehensive and coordinated care for cancer patients and […]

The plaintiff unsuccessfully requested a statistical overview of the number of people who died for individual time periods from various causes after the ÚZIS. These questions may undoubtedly be a matter of legitimate public interest and therefore part of the public domain. According to the Constitutional Court (even taking into account the established jurisprudence of […]

The paper Delphi methodology in healthcare research: How to decide its appropriateness by P. Nasa, R. Jain, and D. Juneja appeared in the last year. Of course, this is not the first and certainly not the last paper dealing with the use of Delphi methods in healthcare, however, its clarity supports its introduction to Czech […]

Three perspectives are most commonly used in economic evaluations in the healthcare sector: (1) the payer perspective, which includes only the costs and utility of a particular party such as the patient, employer, or insurer; (2) the health care perspective, which includes only the costs and utility within the health care sector; and last but […]

Managed entry agreements (MEA) are arrangements that address uncertainty about the performance of technologies (mainly medicines) and simultaneously manage their adoption in order to maximize their effective use, or limit their budget impact. Basically, MEAs can be understood as a tool that gives patients an access to new medicines, while the risk of uncertain effectiveness […]

The early stage HTA (eHTA) is an assessment of health technologies at the stage of research and development. Lately, it has been an intensely investigated area of health technology assessment, most commonly used as a tool for identifying economic predictions of health technologies at an early stage of development, before clinical testing, and even before […]

Gajdoš, O.; Kamenský, V.; Doskočilová, K.; Caithamlová, M.; Kubátová, I. Cost-utility analysis of cardiovascular outpatient rehabilitation care and spa treatment care for patients with heart diseaseCost Effectiveness and Resource Allocation. 2020, 18(1), 1-10. ISSN 1478-7547.